Published in Hepatology on April 01, 2010
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol (2014) 5.71
Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature (2014) 1.57
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol (2016) 1.44
Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A (2012) 1.31
Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol (2011) 1.02
Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. Hepatology (2011) 0.97
AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence. Mol Ther (2012) 0.93
AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo. Hum Gene Ther (2012) 0.90
The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J Virol (2012) 0.90
Perinatal gene transfer to the liver. Curr Pharm Des (2011) 0.84
Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease. Stem Cell Res (2014) 0.84
Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications. Mol Ther (2015) 0.83
Adeno-associated Virus as a Mammalian DNA Vector. Microbiol Spectr (2015) 0.82
A universal system to select gene-modified hepatocytes in vivo. Sci Transl Med (2016) 0.82
In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice. Mol Ther (2012) 0.81
rAAV-mediated tumorigenesis: still unresolved after an AAV assault. Mol Ther (2012) 0.81
Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Mol Pain (2014) 0.80
Efficient liver gene transfer with foamy virus vectors. Med Sci Monit Basic Res (2013) 0.76
Future of rAAV gene therapy: Platform for RNAi, Gene Editing and Beyond. Hum Gene Ther (2017) 0.76
CRISPR/Cas9 - Mediated Precise Targeted Integration In Vivo Using a Double Cut Donor with Short Homology Arms. EBioMedicine (2017) 0.75
Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks. Biomed Res Int (2016) 0.75
Gene therapy -- promises, problems and prospects. Nature (1997) 6.02
Repeat-induced gene silencing in mammals. Nat Genet (1998) 4.74
A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc (2008) 4.02
Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet (1996) 4.00
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Human gene targeting by viral vectors. Nat Genet (1998) 3.02
Mechanisms of eukaryotic DNA double strand break repair. Front Biosci (2006) 2.98
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet (1995) 2.62
Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther (2008) 2.54
Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther (2003) 2.49
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
Gene targeting in vivo by adeno-associated virus vectors. Nat Biotechnol (2006) 2.03
Specific mutations induced by triplex-forming oligonucleotides in mice. Science (2000) 1.98
In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat Med (1998) 1.98
Kinetics of liver repopulation after bone marrow transplantation. Am J Pathol (2002) 1.85
Introduction of single base substitutions at homologous chromosomal sequences by adeno-associated virus vectors. Mol Ther (2001) 1.77
Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol Ther (2001) 1.74
Gene targeting with viral vectors. Mol Ther (2005) 1.42
Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol (2006) 1.36
Precise hit: adeno-associated virus in gene targeting. Nat Rev Microbiol (2005) 1.36
The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis (2001) 1.32
Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. Proc Natl Acad Sci U S A (2001) 1.28
Increased efficiency of oligonucleotide-mediated gene repair through slowing replication fork progression. Proc Natl Acad Sci U S A (2005) 1.26
Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology (2000) 1.26
High-fidelity correction of mutations at multiple chromosomal positions by adeno-associated virus vectors. J Virol (1999) 1.24
Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther (2003) 1.10
Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Mol Ther (2003) 1.08
Gene therapy progress and prospects: targeted gene repair. Gene Ther (2005) 1.08
Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide. Proc Natl Acad Sci U S A (1999) 1.07
Adeno-associated virus vectors and hematology. Blood (1999) 1.03
Gene therapy for the hemophilias. Proc Natl Acad Sci U S A (1999) 1.01
In vivo selection of wild-type hematopoietic stem cells in a murine model of Fanconi anemia. Blood (1999) 0.99
Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus of mice. J Virol (2003) 0.99
Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab (2002) 0.99
Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina. Mol Vis (2007) 0.95
Liver cell transplantation leads to repopulation and functional correction in a mouse model of Wilson's disease. J Gastroenterol Hepatol (2004) 0.92
Transgenic mouse models for studying mutations in vivo: applications in aging research. Mech Ageing Dev (1997) 0.85
Active transcription promotes single-stranded oligonucleotide mediated gene repair. Biochem Biophys Res Commun (2006) 0.82
Identification of mutations from phenotype-driven ENU mutagenesis in mouse chromosome 7. Mamm Genome (2005) 0.82
A LacZ-based transgenic mouse for detection of somatic gene repair events in vivo. Gene Ther (2004) 0.79
Percutaneous intravenous injection in neonatal mice. Comp Med (2000) 0.77
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Biallelic inactivation of BRCA2 in Fanconi anemia. Science (2002) 9.31
Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 6.95
Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature (2003) 6.92
The Fanconi anaemia/BRCA pathway. Nat Rev Cancer (2003) 5.89
RNA interference in adult mice. Nature (2002) 5.33
Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol (2007) 5.04
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature (2013) 4.94
Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther (2006) 4.64
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
A nonviral minicircle vector for deriving human iPS cells. Nat Methods (2010) 4.42
S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood (2002) 4.27
Generation and regeneration of cells of the liver and pancreas. Science (2008) 4.21
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat Med (2004) 3.77
Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol (2009) 3.70
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev (2003) 3.58
Stem cells and liver regeneration. Gastroenterology (2009) 3.40
Human tRNA-derived small RNAs in the global regulation of RNA silencing. RNA (2010) 3.40
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol (2005) 3.28
The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature (2010) 3.27
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol (2003) 3.15
High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol (2005) 3.10
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
The origin and liver repopulating capacity of murine oval cells. Proc Natl Acad Sci U S A (2003) 2.99
Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther (2003) 2.95
The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol (2006) 2.94
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest (2011) 2.83
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell (2003) 2.71
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics (2005) 2.55
Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol (2002) 2.54
Foxl1-Cre-marked adult hepatic progenitors have clonogenic and bilineage differentiation potential. Genes Dev (2011) 2.53
Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther (2003) 2.49
Epigenomic plasticity enables human pancreatic α to β cell reprogramming. J Clin Invest (2013) 2.38
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol (2002) 2.31
Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell (2012) 2.26
Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol (2004) 2.20
Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. Genes Dev (2011) 2.17
Myeloid lineage progenitors give rise to vascular endothelium. Proc Natl Acad Sci U S A (2006) 2.13
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. Blood (2004) 2.08
Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther (2005) 2.06
Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther (2008) 2.01
Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol (2004) 1.97
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest (2010) 1.91
Kinetics of liver repopulation after bone marrow transplantation. Am J Pathol (2002) 1.85
The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo. Cell (2012) 1.84
Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res (2012) 1.84
Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity (2013) 1.83
Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc Natl Acad Sci U S A (2006) 1.82
Therapeutic liver reconstitution with murine cells isolated long after death. Gastroenterology (2010) 1.78
Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell (2008) 1.75
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Patients with biliary atresia have elevated direct/conjugated bilirubin levels shortly after birth. Pediatrics (2011) 1.75
Site-directed transposon integration in human cells. Nucleic Acids Res (2007) 1.74
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol (2002) 1.71
Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet (2007) 1.67
Surface markers for the murine oval cell response. Hepatology (2008) 1.65
In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther (2005) 1.59
Production of pluripotent stem cells by oocyte-assisted reprogramming: joint statement with signatories. Natl Cathol Bioeth Q (2005) 1.57
Mutations in PHF6 are associated with Börjeson-Forssman-Lehmann syndrome. Nat Genet (2002) 1.57
GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology (2006) 1.55
Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest (2006) 1.54
Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest (2012) 1.52
Adenovirus transduction is required for the correction of diabetes using Pdx-1 or Neurogenin-3 in the liver. Mol Ther (2007) 1.51
Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol Ther (2002) 1.51
Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther (2007) 1.51
Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther (2007) 1.50
Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther (2008) 1.49
Consequences of copper accumulation in the livers of the Atp7b-/- (Wilson disease gene) knockout mice. Am J Pathol (2006) 1.47
Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation (2009) 1.45
Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers. Stem Cell Res (2008) 1.45
Generation of monoclonal antibodies specific for cell surface molecules expressed on early mouse endoderm. Stem Cells (2009) 1.43
Rotavirus viremia and extraintestinal viral infection in the neonatal rat model. J Virol (2006) 1.43
Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Mol Ther (2003) 1.42
Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum Mutat (2003) 1.42
Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther (2008) 1.40
Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther (2007) 1.40